Dabuzalgron
Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function[1].
Product Specifications
CAS Number
219311-44-1
Product Name Alternative
Ro 115-1240
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Adrenergic Receptor; Apoptosis
Type
Reference compound
Related Pathways
Apoptosis; GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Endocrinology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/dabuzalgron.html
Purity
98.72
Solubility
DMSO : 26 mg/mL (ultrasonic)
Smiles
CS(=O)(NC1=C(Cl)C=CC(OCC2=NCCN2)=C1C)=O
Molecular Formula
C12H16ClN3O3S
Molecular Weight
317.79
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
α adrenergic receptor
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
RANKL (TNFSF11) (NM_033012) Human Recombinant Protein
TWIST Polyclonal Antibody, AbBy Fluor™ 680 Conjugated
Rabbit anti-Escherichia coli (strain K12) INSD8 Polyclonal Antibody